跳至主要内容
临床试验/ACTRN12621000077864
ACTRN12621000077864已完成未知

Effect of photoreceptor-directed light therapy on sleep in Parkinson's disease

Queensland University of Technology0 个研究点目标入组 60 人开始时间: 2021年1月29日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • People with PD based on the unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Hoehn & Yahr staging (I-IV).
  • Healthy eyes with no anterior eye disease (i.e. lens opacities < grade 2 based on LOCS III) and no signs of retinal or optic nerve disease (diabetic retinopathy, glaucoma or age-related macular degeneration) based on ophthalmic examination (determined by an ophthalmologist, PI Feigl)
  • Living independently in the community and able to walk unaided

排除标准

  • Inability to comply with study follow up
  • Participants having travelled across 2 or more time zones within 90 days before start of the study
  • Dementia based on MMSE (<24) and ACE (<82) assessments
  • Deep brain stimulation, other device assisted therapies (i.e. red light therapy) or CNS surgery
  • Any type of systemic disease or any medical condition (controlled or uncontrolled) other than PD that could be expected to significantly affect the health of a participant
  • A periodic limb movement disorder index (PLMI) > 15/hour in PSG
  • Significant sleep apnea (AHI apnoea-hypnoea index > 15 events/hour) and loss of REM atonia in PSG
  • Recent or recurrent history of musculoskeletal injury or surgery

研究者

相似试验